Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253305 · ClinicalTrials.gov registry record · Phase 2
Topical Gel Anti-Fungal Agent for Tinea Unguium
A Phase 2 study, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00253305 is a Phase 2 study that has completed, run by MediQuest Therapeutics. The registered enrollment target is 75 participants.
The verdict
NCT00253305, a Phase 2 study, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety. Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.
Interventions
- DRUG Organogel of naftifine, 2%
- DRUG Organogel of terbinafine, 2%
- DRUG Organogel of naftifine, 6%
- DRUG Organogel of terbinafine, 6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253305
The ClinicalTrials.gov registry entry for NCT00253305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediQuest Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Organogel of naftifine, 2% is the first listed.
NCT00253305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00253305 about?
NCT00253305 is a clinical study titled "Topical Gel Anti-Fungal Agent for Tinea Unguium". The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used a...
What is the current status of trial NCT00253305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00253305?
The interventions under investigation include: Organogel of naftifine, 2% (DRUG), Organogel of terbinafine, 2% (DRUG), Organogel of naftifine, 6% (DRUG), Organogel of terbinafine, 6% (DRUG).
Who is sponsoring clinical trial NCT00253305?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.